In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Getting design and engineering teams on the same page about what digital product to create and how to build it continues to be a challenge. A lot of companies find themselves dealing with scattered ...

Last night, '90s emo pioneers Knapsack reunited for a show at Soda Bar in San Diego, CA. The one-off show was announced this past June and precedes the band's appearance at Best Friends Festival later ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Another name for brute force is exhaustive search. In these algorithms you consider every possible solution in the solution domain to find the optimal solution. Depending on the type of problem that ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Abstract: The knapsack problem is a classic NP-hard optimization challenge with wide-ranging applications in computer science, such as resource allocation. While several variants have been developed, ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...